Logo of The Journal of Bone & Joint Surgery (Br)
Quick search:        
          Advanced Search
Guest Access | Sign In
Journal of Bone and Joint Surgery - British Volume, Vol 89-B, Issue 2, 155-159.
doi: 10.1302/0301-620X.89B2.17747  
Copyright © 2007 by British Editorial Society of Bone and Joint Surgery
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Japanese
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow My Folders
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (4)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Saudan, M.
Right arrow Articles by Hoffmeyer, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Saudan, M.
Right arrow Articles by Hoffmeyer, P.

Celecoxib versus ibuprofen in the prevention of heterotopic ossification following total hip replacement

A PROSPECTIVE RANDOMISED TRIAL

M. Saudan, MD, Orthopaedic Surgeon1; P. Saudan, MD, Physician2; T. Perneger, PhD, Professor3; N. Riand, MD, Orthopaedic Surgeon1; A. Keller, MD, Physician4; and P. Hoffmeyer, MD, Professor1

1 Division of Orthopaedic Surgery
2 Division of Nephrology
3 Quality of Care Unit
4 Department of Radiology, University Hospitals of Geneva, Rue Micheli-du-Crest 24, CH-1211, Genèva 14, Switzerland.

Correspondence should be sent to Dr M. Saudan; e-mail: marc.saudan{at}hcuge.ch

We examined whether a selective cyclooxygenase-2 (COX-2) inhibitor (celecoxib) was as effective as a non-selective inhibitor (ibuprofen) for the prevention of heterotopic ossification following total hip replacement. A total of 250 patients were randomised to receive celecoxib (200 mg b/d) or ibuprofen (400 mg t.d.s) for ten days after surgery. Anteroposterior radiographs of the pelvis were examined for heterotopic ossification three months after surgery. Of the 250 patients, 240 were available for assessment. Heterotopic ossification was more common in the ibuprofen group (none 40.7% (50), Brooker class I 46.3% (57), classes II and III 13.0% (16)) than in the celecoxib group (none 59.0% (69), Brooker class I 35.9% (42), classes II and III 5.1% (6), p = 0.002). Celecoxib was more effective than ibuprofen in preventing heterotopic bone formation after total hip replacement.




This article has been cited by other articles:


Home page
 J Bone Joint Surg BrHome page
T. W. Axelrad, B. Steen, D. W. Lowenberg, W. R. Creevy, and T. A. Einhorn
Heterotopic ossification after the use of commercially available recombinant human bone morphogenetic proteins in four patients
J Bone Joint Surg Br, December 1, 2008; 90-B(12): 1617 - 1622.
[Abstract] [Full Text] [PDF]


(c) British Editorial Society of Bone and Joint Surgery All Rights Reserved
Registered charity no: 209299     Print ISSN: 0301-620X
Hip, Knee, Trauma, Upper limb, Foot & Ankle, Paediatrics, Oncology, Spine, Arthroplasty, General